Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM6A | O15550 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937494 | 0.70 | LMNA (0.46) | CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL7154082 | 0.69 | LMNA (0.35) | ACHECYP2D6TSHRGSK3B | |
| SCHEMBL100263 | 0.65 | CRBN (0.44) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL17226145 | 0.63 | CYP2D6 (0.31) | ACHECYP2D6TSHR | |
| Trimethylammonium SCHEMBL9619224 | 0.63 | ACHE (0.36) | ACHEKDM2BKDM2ACYP2D6TSHR | |
| SCHEMBL23222667 | 0.62 | CRBN (0.37) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL2078819 | 0.62 | CRBN (0.37) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL19577292 | 0.62 | CRBN (0.37) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL5478056 | 0.62 | KDM4E (0.35) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL7607451 | 0.61 | ADORA2B (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | ITO, KABUSIKIKAISYA (JP) | 2023-02-23 | — | — | US | claimed |
| US-8486722-B1 | Sensing method for biopolymers and sensing device therefor | NATIONAL UNIVERSITY CORPORATION TOYOHASHI UNIVERSITY OF TECHNOLOGY (JP) | 2013-07-16 | — | — | US | claimed |
| US-20130164862-A1 | SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR | TANAKA SABURO (JP) | 2013-06-27 | — | — | US | claimed |
| US-20070218567-A1 | SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR | NATIONAL UNIV CORP TOYOHASHI UNIV OF TECHNOLOGY (JP) | 2007-09-20 | — | — | US | claimed |
| CN-115135307-B | Cell delivery vehicle | 株式会社ITO | 2024-11-22 | — | — | CN | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4182736-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-05-24 | — | — | EP | disclosed |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | ITO, KABUSIKIKAISYA (JP) | 2023-02-23 | — | — | US | disclosed |
| CN-115135307-A | Carrier for cell delivery | 株式会社ITO | 2022-09-30 | — | — | CN | disclosed |
| WO-2022012798-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| US-20190170758-A1 | METHOD OF DETECTION WITH A FLUORESCENT LABELING PARTICLE | FURUKAWA ELECTRIC CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10203326-B2 | Method of detecting target substance | FURUKAWA ELECTRIC CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20110233453-A1 | METHOD OF STORING THERMORESPONSIVE POLYMER IN STATE OF AQUEOUS SOLUTION | CHISSO CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7976728-B2 | Aqueous solution of polymer having upper critical solution temperature, aqueous dispersion of particle modified with the polymer and method of storing the same | JNC CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2009044-B1 | Method of storing an aqueous dispersion of particle modified with a polymer having upper critical solution temperature | JNC CORP (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20090001321-A1 | AQUEOUS SOLUTION OF POLYMER HAVING UPPER CRITICAL SOLUTION TEMPERATURE, AQUEOUS DISPERSION OF PARTICLE MODIFIED WITH THE POLYMER AND METHOD OF STORING THE SAME | CHISSO CORPORATION (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090001025-A1 | AGGREGATION AND DISPERSION METHODS OF MAGNETIC PARTICLES, SEPARATION AND DETECTION METHODS USING THE SAME AND DETECTION KIT | CHISSO CORPORATION (JP) | 2009-01-01 | — | — | US | disclosed |
| EP-2009044-A1 | Aqueous solution of polymer having upper critical solution temperature, aqueous dispersion of particle modified with the polymer and method of storing the same | Chisso Corporation (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2009442-A2 | Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit | Chisso Corporation (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20070218567-A1 | SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR | NATIONAL UNIV CORP TOYOHASHI UNIV OF TECHNOLOGY (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | CTSA, ATG4A, ATG7 | ACHE 3074/4885KDM4E 3872/4885KDM6A 2362/4885 |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | ACHE 635/4885KDM4E 3587/4885KDM6A 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.